Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting

Current Opinion in Infectious Diseases

Volumn 18, Issue 4, 2005, Pages 306-313

  Navon Venezia, Shiri ^a   Ben Ami, Ronen ^a   Carmeli, Yehuda ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Acinetobacter baumannii; Emergence of resistance; Epidemiology; Multi drug resistance; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; DISINFECTANT AGENT; MONOCLONAL ANTIBODY; O ANTIGEN; OPRF VACCINE; OPRI VACCINE; PENICILLIN DERIVATIVE; PSEUDOMONAS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT VACCINE; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CELL INTERACTION; GENETIC RESISTANCE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; IMMUNOTHERAPY; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 22544477125     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000171920.44809.f0     Document Type: Review

References (81)

1. Moore JE, Heaney N, Millar BC, et al. Incidence of Pseudomonas aeruginosa in recreational and hydrotherapy pools. Commun Dis Public Health 2002; 5:23-26.
2. Fiorillo L, Zucker M, Sawyer D, Lin AN. The Pseudomonas hot-foot syndrome. N Engl J Med 2001; 345:335-338.
3. Blanc DS, Nahimana I, Petignat C, et al. Faucets as a reservoir of endemic Pseudomonas aeruginosa colonization/infections in intensive care units. Intensive Care Med 2004; 30:1964-1968.
4. Thuong M, Arvaniti K, Ruimy R, et al. Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit. J Hosp Infect 2003; 53:274-282.
5. Crespo MP, Woodford N, Sinclair A, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004; 42:5094-5101.
6. Ferreira AC, Gobara S, Costa SE, et al. Emergence of resistance in Pseudomonas aeruginosa and Acinetobacter species after the use of antimicrobials for burned patients. Infect Control Hosp Epidemiol 2004; 25:868-872.
7. Tsukayama DT, van Loon HJ, Cartwright C, et al. The evolution of Pseudomonas aeruginosa during antibiotic rotation in a medical intensive care unit: the RADAR-trial. Int J Antimicrob Agents 2004; 24:339-345.
8. Valles J, Mariscal D, Cortes P, et al. Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia. Intensive Care Med 2004; 30:1768-1775. The study provides insight into the spread of P. aeruginosa.
9. Defez C, Fabbro-Peray P, Bouziges N, et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 2004; 57:209-216.
10. Mohr JF, Jones A, Ostrosky-Zeichner L, et al. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. Int J Antimicrob Agents 2004; 24:346-351.
11. Paramythiotou E, Lucet JC, Timsit JF, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004; 38:670-677. The study describes risk factors for MDR P. aeruginosa.
12. Ortega B, Groeneveld AB, Schultsz C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epidemiol 2004; 25:825-831.
13. Van Looveren M, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10:684-704. An excellent review on Acinetobacter spp.
14. Berlau J, Aucken H, Malnick H, Pitt T. Distribution of Acinetobacter species on skin of healthy humans. Eur J Clin Microbiol Infect Dis 1999; 18:179-183.
15. Chu YW, Leung CM, Houang ET, et al. Skin carriage of Acinetobacters in Hong Kong. J Clin Microbiol 1999; 37:4206.
16. Weingarten CM, Rybak MJ, Jahns BE, et al. Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital. Pharmacotherapy 1999; 19:1080-1085.
17. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-317. An important large-scale analysis of nosocomial bacteremia.
18. Rodriguez-Bano J, Cisneros JM, Fernandez-Cuenca F, et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 2004; 25:819-824.
19. Manikal VM, Landman D, Saurina G, et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31:101-106.
20. Villegas MV, Hartstein AI. Acinetobacter outbreaks 1977-2000. Infect Control Hosp Epidemiol 2003; 24:284-295.
21. Corbella X, Montera A, Pujol M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38:4086-4095.
22. Gales AC, Jones RN, Forward KR, et al. Emerging importance of multidrug-resistant Acinetobacter species and Stentrophomonas maltophilia as pathogens in seriously III patients: geographic patterns, epidemiological features and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001; 32(Suppl 2):104-113.
23. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet North Am Ed 1994; 344:1329-1332.
24. Turton JF, Kaufmann ME, Warner M, et al. A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England. J Hosp Infect 2004; 58:170-179.
25. El Shafie SS, Alishaq M, Leni Garcia M. Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in trauma intensive care unit. J Hosp Infect 2004; 56:101-105.
26. Wroblewska MM, Dijkshoorn L, Marchel H, et al. Outbreak of nosocomial meningitis caused by Acinetobacter baumannii in neurosurgical patients. J Hosp Infect 2004; 57:300-307.
27. Maragakis LL, Cosgrove SE, Song X, et al. An outbreak of multidrug-resistant Acinetobacter baumannii associated with pulsatile lavage wound treatment. JAMA 2004; 292:3006-3011. Outbreak investigation of MDR A. baumannii which illustrates the epidemiology of this epidemic organism, and describes measures for control.
28. Denton M, Wilcox MH, Parnell P, et al. Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit. J Hosp Infect 2004; 56:106-110.
29. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep 2004; 53:1063-1066. An interesting report on the occurrence of A. baumannii in military patients.
30. Abbo A, Navon-Venezia S, Hammer-Muntz O, et al. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11:22-29. Risk factors and molecular epidemiology of MDR A. baumannii
31. . 31 Nemec A, Dijkshoorn L, van der Reijden TJ. Long-term predominance of two pan-European clones among multi-resistant Acinetobacter baumannii strains in the Czech Republic. J Med Microbiol 2004; 53:147-15
32. 32 Van Dessel H, Dijkshoorn L, van der Reijden T, et al. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res Microbiol 2004; 155:105-112.
33. Fetiye K, Karadenizli A, Okay E, et al. Comparison in a rat thigh abscess model of imipenem, meropenem and cefoperazone-sulbactam against Acinetobacter baumannii strains in terms of bactericidal efficacy and resistance selection. Ann Clin Microbiol Antimicrob 2004; 3:2.
34. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-1132.
35. D'Agata EM. Rapidly rising prevalence of nosocomial multidrug-resistant. Gram-negative bacilli: a 9-year surveillance study. Infect Control Hosp Epidemiol 2004; 25:842-846.
36. Jung R, Fish DN, Obritsch MD, MacLaren R. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital. J Hosp Infect 2004; 57:105-111.
37. Karlowsky JA, Jones ME, Thornsberry C, et al. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 2005; 40(Suppl 2):S89-S98. The study describes recent data on the resistance profile of P. aeruginosa clinical strains in the USA.
38. Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum β-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003; 47:2385-2392.
39. Nordmann P, Naas T. Sequence analysis of PER-1 extended-spectrum β-lactamase from Pseudomonas aeruginosa and comparison with class A β-lactamases. Antimicrob Agents Chemother 1994; 38:104-114.
40. Poirel L, Rotimi VO, Mokaddas EM, et al. VEB-1-like extended-spectrum β-lactamases in Pseudomonas aeruginosa, Kuwait. Emerg Infect Dis 2000; 17:468-470.
41. Castanheira M, Mendes RE, Walsh TR, et al. Emergence of the extended-spectrum beta-lactamase GES-1 in a Pseudomonas aeruginosa strain from Brazil: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2004; 48:2344-2345.
42. GES-1 and a fused product of aac(3)-lb/aac(6′)-lb′ gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46:638-645.
43. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8:321-331.
44. Castanheira M, Toleman MA, Jones RN, et al. Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase. Antimicrob Agents Chemother 2004; 48:4654-4661. A description of a new type of carbapenemases.
45. Lagatolla C, Tonin EA, Monti-Bragadin C, et al. Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-beta-lactamase determinants in European hospital. Emerg Infect Dis 2004; 10: 535-538.
46. Lee K, Ha GY, Shin BM, et al. Metallo-beta-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. Diagn Microbiol Infect Dis 2004; 50:51-58.
47. Rowe-Magnus DA, Mazel D. The role of integrons in antibiotic resistance gene capture. Int J Med Microbiol 2002; 292:115-125.
48. Rice LB. Association of different mobile elements to generate novel integrative elements. Cell Mol Life Sci 2002; 59:2023-2032.
49. Da Silva GJ, Quinteira S, Bertolo E, et al. Long-term dissemination of an OXA-40 carbapenemase-producing Acinetobacter baumannii clone in the Iberian Peninsula. J Antimicrob Chemother 2004; 54:255-258.
50. Heritier C, Dubouix A, Poirel L, et al. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. J Antimicrob Chemother 2005; 55:115-118.
51. Mendes RE, Castanheira M, Garcia P, et al. First isolation of bla(VIM-2) in Latin America: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2004; 48:1433-1434.
52. Yatsuyanagi J, Saito S, Ito Y, et al. Identification of Pseudomonas aeruginosa clinical strains harboring the bla(VIM-2) metallo-beta-lactamase gene in Akita Prefecture. Japan Jpn J Infect Dis 2004; 57:130-132.
53. Yatsuyanagi J, Saito S, Harata S, et al. Class 1 integron containing metallo-beta-lactamase gene blaVIM-2 in Pseudomonas aeruginosa clinical strains isolated in Japan. Antimicrob Agents Chemother 2004; 48:626-628.
54. Patzer J, Toleman MA, Deshpande LM, et al. Pseudomonas aeruginosa strains harbouring an unusual blaVIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). J Antimicrob Chemother 2004; 53:451-456.
55. Toleman MA, Rolston K, Jones RN, Walsh TR. blaVIM-7, an evolutionary distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother 2004; 48:329-332.
56. Koh TH, Wang GC, Sng LH. Clonal spread of IMP-1-producing Pseudomonas aeruginosa in two hospitals in Singapore. J Clin Microbiol 2004; 42:5378-5380.
57. Wang CX, Mi ZH. IMP-1 metallo-beta-lactamase-producing Pseudomonas aeruginosa in a university hospital in the People's Republic of China. J Antimicrob Chemother 2004; 54:1159-1160.
58. Peleg AY, Franklin C, Bell J, Spelman DW. Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. J Antimicrob Chemother 2004; 54:699-700.
59. Mendes RE, Toleman MA, Ribeiro J, et al. Integron carrying a novel metallo-beta-lactamase gene, blaIMP-16, and a fused form of aminoglycoside- resistant gene aac(6′)-30/aac(6′)-lb′: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2004; 48:4693-4702.
60. Boles BR, Thoendel M, Singh PK. Self-generated diversity produces 'insurance effects' in biofilm communities. Proc Natl Acad Sci U S A 2004; 101:16630-16635.
61. Jackson KD, Starkey M, Kremer S, et al. Identification of psl, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PAO1 biofilm formation. J Bacteriol 2004; 186:4466-4475. An essential genetic locus necessary for P. aeruginosa biofilm formation.
62. Bagge N, Schuster M, Hentzer M, et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production. Antimicrob Agents Chemother 2004; 48:1175-1187. The study sheds light on the effect of imipenem on gene expression in the biofilm population.
63. Cobb LM, Mychaleckyj JC, Wozniak DJ, Lopez-Boado YS. Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease. J Immunol 2004; 173:5659-5670. A comprehensive research for improved understanding of the Pseudomonas state during cystic fibrosis disease.
64. Hermann C, Hermann J, Munzel U, et al. Bacterial flora accompanying Candida yeasts in clinical specimens. Mycoses 1999; 42:619-627.
65. Hogan DA, Vik A, Kolter R, et al. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol 2004; 54:1212-1223. An elegant study describing microbial interactions in the same infection site.
66. Kerr JR. Suppression of fungal growth exhibited by Pseudomonas aeruginosa. J Clin Microbiol 1994; 32:525-527.
67. Smith MG, Des Etages SG, Snyder M, et al. Microbial synergy via an ethanol-triggered pathway. Mol Cell Biol 2004; 24:3874-3884.
68. Blondeau JM, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16(Suppl 3):1-19.
69. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668. An excellent summary on combination therapy.
70. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-527.
71. Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis 2005; 15(Suppl 2):S105-S114.
72. Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37:e154-e160.
73. Tascini C, Gemignani G, Ferranti S, et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 2004; 16:282-287.
74. Montera A, Ariza J, Corbella X, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54:1085-1091.
75. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48:4479-4481.
76. Nagata T, Mukae H, Kadota J, et al. Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. Antimicrob Agents Chemother 2004; 48:2251-2259.
77. Imamura Y, Yanagihara K, Mizuta Y, et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-oxododecanoyl) homoserine lactone in NCI-H292 cells. Antimicrob Agents Chemother 2004; 48:3457-3461.
78. Holder IA. Pseudomonas immunotherapy: a historical overview. Vaccine 2004;22:831-839. A comprehensive review of the aspects of immunotherapy of P. aeruginosa infection on all its aspects.
79. Baumann U, Mansouri E, von Specht BU. Recombinant OprF-Oprl as a vaccine against Pseudomonas aeruginosa infections. Vaccine 2004; 22:840-847. Recent successive clinical trial results for induction of anti-Pseudomonas antibodies against two vaccine formulations.
80. Digiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect Immun 2004; 72:7012-7021.
81. Lang AB, Rudeberg A, Schoni MH, et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 2004; 23:504-510.